Sue Perron
About Sue Perron
Sue Perron is a Sr Preclinical Research Associate at Boston Scientific with extensive experience in research and development roles at various companies, contributing significantly to medical device innovations and FDA approvals.
Company
Sue Perron currently works at Boston Scientific as a Senior Preclinical Research Associate. Previously, she has held positions at WuXi AppTec, EnteroMedics, HeartStent, and Varitronic Systems, Inc. Her extensive experience in the medical device and clinical research fields has built a solid foundation for her role at Boston Scientific.
Title
Sue Perron holds the title of Senior Preclinical Research Associate at Boston Scientific. In this role, she leverages her deep expertise to contribute significantly to preclinical research projects, ensuring the development of safe and effective medical devices.
Education and Expertise
Sue Perron earned her Bachelor of Arts degree in Chemistry and Biology from Bethel University. She also undertook post-baccalaureate coursework at the University of Minnesota-Twin Cities to further support her career goals. Her educational background has provided a strong foundation for her extensive career in the medical and clinical research fields.
Previous Experience
Sue Perron has a diverse background with previous roles in several prominent organizations. At WuXi AppTec, she served as a Study Director from 2016 to 2018. As a Research Scientist at EnteroMedics, she contributed from 2003 to 2015, and at HeartStent from 1998 to 2002. She also held the position of Senior Chemist at Boston Scientific from 1989 to 1998, and worked as an R&D Chemist at Varitronic Systems, Inc from 1986 to 1989. Early in her career, she gained valuable experience as a Tech Aide at 3M.
Achievements
Throughout her career, Sue Perron has achieved several notable milestones. She developed novel coronary stent prototypes using electron microscopy, leading to the creation of a new global product. She played a crucial role in obtaining FDA approval for a novel device to treat morbid obesity, the first such approval in nearly a decade. Additionally, her contributions to the design of devices for coronary angioplasty procedures and stent devices significantly increased corporate revenue. She has effectively managed clinical trial master files, resulting in positive FDA audit outcomes, and mitigated manufacturing issues through materials research.